ORIC Pharmaceuticals (ORIC) PT Raised to $15 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts ORIC Hot Sheet
Price: $9.59 --0%
Rating Summary:
17 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
17 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Oppenheimer analyst Matthew Biegler raised the price target on ORIC Pharmaceuticals (NASDAQ: ORIC) to $15.00 (from $12.00) while maintaining a Outperform rating.
You May Also Be Interested In
- ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
- Goldman Sachs Upgrades Chengdu XGimi Technology Co Ltd (688696:CH) to Neutral
- Hybe Corporation (352820:KS) PT Lowered to KRW250,000 at Citi
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
